ENCEPHALITIS ANTI N-METHYL-D-ASPARTATE RECEPTORS

Shila Suryani; Calcarina Retno Fitriani Wisudarti

doi:10.20884/1.mandala.2023.16.2.8584

Shila Suryani Universitas Jenderal Soedirman
Calcarina Retno Fitriani Wisudarti Universitas Gadjah Mada

DOI: https://doi.org/10.20884/1.mandala.2023.16.2.8584

Abstract

Background : Anti-N-Methyl-D-Aspartate receptor encephalitis is an autoimmune disease where the incidence is still rare which is characterized by complex neuropsychiatric syndrome. In severe stages, it can cause morbidity and mortality so it requires adequate intensive therapeutic management. Cases: 1) Male, 23 years old diagnosed with NMDAR encephalitis at an advanced stage in 10 days of treatment. Patient was given plasma exchange therapy three times and steroids did not respond then given rituximab, did not respond as expected. 2) A 19-year-old male diagnosed with NMDAR encephalitis at an advanced stage on the 7th day of hospitalization. Patient was given plasma exchange therapy 7 times and steroids. The patient showed an improved response to the third plasma exchange therapy, the patient could weaned from the ventilator and then transferred from the ICU. Conclusion: NMDAR encephalitis at an advanced stage requires long intensive care. Immunotherapy is the first-line therapy for NMDAR encephalitis. Immunotherapy options in severe cases can be given plasma exchange in combination with steroids. Rapid diagnosis and early initiation of therapy can provide better outcomes, reduce complications of nosocomial infections and reduce length of stay in the ICU.

References

Barry, H., Byrne, S., Barrett, E., Murphy, K.C., Cotter, D.R., 2015. Anti- N -methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment . BJPsych Bull 39, 19–23. https://doi.org/10.1192/pb.bp.113.045518

Dalmau, J., Armangué, T., Planagumà, J., Radosevic, M., Mannara, F., Leypoldt, F., Geis, C., Lancaster, E., Titulaer, M.J., Rosenfeld, M.R., Graus, F., 2019. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. https://doi.org/10.1016/S1474-4422(19)30244-3

Graus, F., Titulaer, M.J., Balu, R., Benseler, S., Bien, C.G., Cellucci, T., Cortese, I., Dale, R.C., Gelfand, J.M., Geschwind, M., Glaser, C.A., Honnorat, J., Höftberger, R., Iizuka, T., Irani, S.R., Lancaster, E., Leypoldt, F., Prüss, H., Rae-Grant, A., Reindl, M., Rosenfeld, M.R., Rostásy, K., Saiz, A., Venkatesan, A., Vincent, A., Wandinger, K.P., Waters, P., Dalmau, J., 2016. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. https://doi.org/10.1016/S1474-4422(15)00401-9

Hallowell, S., Tebedge, E., Oates, M., Hand, E., 2017. Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. J Pediatr Pharmacol Ther 22, 118–123. https://doi.org/10.583/1551-6776-22.2.118

Iizuka, T., Sakai, F., Ide, T., Monzen, T., Yoshii, S., Iigaya, M., Suzuki, K., Lynch, D.R., Suzuki, N., Hata, T., Dalmau, J., 2008. Anti-NMDA receptor encephalitis in Japan: Long-term outcome without tumor removal. Neurology 70, 504–511. https://doi.org/10.1212/01.wnl.0000278388.90370.c3

Jiang, Y., Tian, X., Gu, Y., Li, F., Wang, X., 2019. Application of plasma exchange in steroid-reponsive encephalopathy. Front Immunol. https://doi.org/10.3389/fimmu.2019.00324

Maneta, E., Garcia, G., 2014. Psychiatric Manifestations of Anti-NMDA Receptor Encephalitis: Neurobiological Underpinnings and Differential Diagnostic Implications, Psychosomatics.

Thaler, F.S., Zimmermann, L., Kammermeier, S., Strippel, C., Ringelstein, M., Kraft, A., Sühs, K.W., Wickel, J., Geis, C., Markewitz, R., Urbanek, C., Sommer, C., Doppler, K., Penner, L., Lewerenz, J., Rößling, R., Finke, C., Prüss, H., Melzer, N., Wandinger, K.P., Leypoldt, F., Kümpfel, T., 2021. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry. Neurology(R) neuroimmunology & neuroinflammation 8. https://doi.org/10.1212/NXI.0000000000001088

Titulaer, M.J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L.S., Benseler, S.M., Kawachi, I., Martinez-Hernandez, E., Aguilar, E., Gresa-Arribas, N., Ryan-Florance, N., Torrents, A., Saiz, A., Rosenfeld, M.R., Balice-Gordon, R., Graus, F., Dalmau, J., 2013. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 12, 157–165. https://doi.org/10.1016/S1474-4422(12)70310-1

Türkdoǧan, D., Orengul, A.C., Zaimoǧlu, S., Ekinci, G., 2014. Anti-N-Methyl-d-Aspartate (Anti-NMDA) receptor encephalitis: Rapid and sustained clinical improvement with steroid therapy starting in the late phase. J Child Neurol 29, 684–687. https://doi.org/10.1177/0883073813520497

Wang, J., Lin, J., Wang, M., Meng, Z., Zhou, D., Li, J., 2021. High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis. Front Immunol 12. https://doi.org/10.3389/fimmu.2021.774664

Wang, W., Zhang, L., Chi, X.S., He, L., Zhou, D., Li, J.M., 2020. Psychiatric Symptoms of Patients With Anti-NMDA Receptor Encephalitis. Front Neurol 10. https://doi.org/10.3389/fneur.2019.01330

Watkins, C.J., Pei, Q., Newberry, N.R., 1998. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Molecular Brain Research 61, 108–113. https://doi.org/10.1016/S0169-328X(98)00211-3

Zhang, Y., Liu, G., Jiang, M., Chen, W., Su, Y., 2019. Efficacy of Therapeutic Plasma Exchange in Patients with Severe Refractory Anti-NMDA Receptor Encephalitis. Neurotherapeutics 16, 828–837. https://doi.org/10.1007/s13311-019-00725-4